ALK and non-small cell lung carcinoma: Targeted molecular treatments for advanced non-small cell lung cancer (NSCLC) have been revolutionized by the identification of oncogenic activation in specific tyrosine kinases, such as EGFR, ALK, and ROS1, using driver mutations as biomarkers [1,2].